28
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by SHANK3 point mutations

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Phelan-McDermid syndrome (PMS) is a neurodevelopmental disorder characterized by psychiatric and neurological features. Most reported cases are caused by 22q13.3 deletions, leading to SHANK3 haploinsufficiency, but also usually encompassing many other genes. While the number of point mutations identified in SHANK3 has increased in recent years due to large-scale sequencing studies, systematic studies describing the phenotype of individuals harboring such mutations are lacking.

          Methods

          We provide detailed clinical and genetic data on 17 individuals carrying mutations in SHANK3. We also review 60 previously reported patients with pathogenic or likely pathogenic SHANK3 variants, often lacking detailed phenotypic information.

          Results

          SHANK3 mutations in our cohort and in previously reported cases were distributed throughout the protein; the majority were truncating and all were compatible with de novo inheritance. Despite substantial allelic heterogeneity, four variants were recurrent (p.Leu1142Valfs*153, p.Ala1227Glyfs*69, p.Arg1255Leufs*25, and c.2265+1G>A), suggesting that these are hotspots for de novo mutations. All individuals studied had intellectual disability, and autism spectrum disorder was prevalent (73%). Severe speech deficits were common, but in contrast to individuals with 22q13.3 deletions, the majority developed single words, including 41% with at least phrase speech. Other common findings were consistent with reports among individuals with 22q13.3 deletions, including hypotonia, motor skill deficits, regression, seizures, brain abnormalities, mild dysmorphic features, and feeding and gastrointestinal problems.

          Conclusions

          Haploinsufficiency of SHANK3 resulting from point mutations is sufficient to cause a broad range of features associated with PMS. Our findings expand the molecular and phenotypic spectrum of PMS caused by SHANK3 point mutations and suggest that, in general, speech impairment and motor deficits are more severe in the case of deletions. In contrast, renal abnormalities associated with 22q13.3 deletions do not appear to be related to the loss of SHANK3.

          Electronic supplementary material

          The online version of this article (10.1186/s13229-018-0205-9) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Contribution of SHANK3 mutations to autism spectrum disorder.

          Mutations in SHANK3, which encodes a synaptic scaffolding protein, have been described in subjects with an autism spectrum disorder (ASD). To assess the quantitative contribution of SHANK3 to the pathogenesis of autism, we determined the frequency of DNA sequence and copy-number variants in this gene in 400 ASD-affected subjects ascertained in Canada. One de novo mutation and two gene deletions were discovered, indicating a contribution of 0.75% in this cohort. One additional SHANK3 deletion was characterized in two ASD-affected siblings from another collection, which brings the total number of published mutations in unrelated ASD-affected families to seven. The combined data provide support that haploinsufficiency of SHANK3 can cause a monogenic form of autism in sufficient frequency to warrant consideration in clinical diagnostic testing.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability.

            To identify candidate genes for intellectual disability, we performed a meta-analysis on 2,637 de novo mutations, identified from the exomes of 2,104 patient-parent trios. Statistical analyses identified 10 new candidate ID genes: DLG4, PPM1D, RAC1, SMAD6, SON, SOX5, SYNCRIP, TCF20, TLK2 and TRIP12. In addition, we show that these genes are intolerant to nonsynonymous variation and that mutations in these genes are associated with specific clinical ID phenotypes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Recurrent de novo mutations implicate novel genes underlying simplex autism risk

              Autism spectrum disorder (ASD) has a strong but complex genetic component. Here we report on the resequencing of 64 candidate neurodevelopmental disorder risk genes in 5,979 individuals: 3,486 probands and 2,493 unaffected siblings. We find a strong burden of de novo point mutations for these genes and specifically implicate nine genes. These include CHD2 and SYNGAP1, genes previously reported in related disorders, and novel genes TRIP12 and PAX5. We also show that mutation carriers generally have lower IQs and enrichment for seizures. These data begin to distinguish genetically distinct subtypes of autism important for etiological classification and future therapeutics.
                Bookmark

                Author and article information

                Contributors
                silvia.derubeis@mssm.edu
                paige.siper@mssm.edu
                allison.durkin@mssm.edu
                jordana.weissman@mssm.edu
                muratet.francois@orange.fr
                danielle.halpern@mssm.edu
                pilar.trelles@mssm.edu
                yitzchak.frank@mssm.edu
                reymundo.lozano@mssm.edu
                ting.wang@mssm.edu
                holder@bcm.edu
                catalina.betancur@inserm.fr
                +1 (212) 241-0200 , joseph.buxbaum@mssm.edu
                alexander.kolevzon@mssm.edu
                Journal
                Mol Autism
                Mol Autism
                Molecular Autism
                BioMed Central (London )
                2040-2392
                27 April 2018
                27 April 2018
                2018
                : 9
                : 31
                Affiliations
                [1 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Seaver Autism Center, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
                [2 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Department of Psychiatry, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
                [3 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Department of Neurology, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
                [4 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Department of Pediatrics, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
                [5 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Department of Genetics and Genomic Sciences, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
                [6 ]ISNI 0000 0001 2200 2638, GRID grid.416975.8, Division of Neurology and Developmental Neuroscience, Department of Pediatrics, , Baylor College of Medicine and Texas Children’s Hospital, ; Houston, TX 77030 USA
                [7 ]Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine, Institut de Biologie Paris Seine, 75005 Paris, France
                [8 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Department of Neuroscience, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
                [9 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Friedman Brain Institute, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
                [10 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Mindich Child Health and Development Institute, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
                Author information
                http://orcid.org/0000-0001-9383-6883
                http://orcid.org/0000-0002-9659-8232
                http://orcid.org/0000-0002-8686-4146
                http://orcid.org/0000-0003-2798-4858
                http://orcid.org/0000-0001-6745-1197
                http://orcid.org/0000-0002-7442-3677
                http://orcid.org/0000-0003-0979-1032
                http://orcid.org/0000-0002-5616-5854
                http://orcid.org/0000-0002-3322-679X
                http://orcid.org/0000-0001-5595-0458
                http://orcid.org/0000-0002-3327-4804
                http://orcid.org/0000-0001-8898-8313
                http://orcid.org/0000-0001-8129-2671
                Article
                205
                10.1186/s13229-018-0205-9
                5921983
                29719671
                bdcf8fc2-d3ae-442c-9a49-051a693c3348
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 1 February 2018
                : 13 March 2018
                Funding
                Funded by: Beatrice and Samuel A. Seaver Foundation
                Funded by: Phelan-McDermid Syndrome Foundation
                Funded by: FundRef http://dx.doi.org/10.13039/100000025, National Institute of Mental Health;
                Award ID: R34 MH100276-01
                Award ID: R21 MH107839
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000065, National Institute of Neurological Disorders and Stroke;
                Award ID: U54 NS092090-01
                Award ID: K08 NS091381
                Award Recipient :
                Funded by: Robbins Foundation
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Neurosciences
                shank3,phelan-mcdermid syndrome,22q13 deletion syndrome,sequence variants,phenotype,autism spectrum disorder,intellectual disability

                Comments

                Comment on this article